BioDuro

BioDuro is an American contract research, development, and manufacturing organization, or CRDMO, headquartered in Irvine, California. The company provides outsourced scientific and manufacturing services to pharmaceutical, biotechnology, and other life-science customers. Its stated scope extends from early discovery and preclinical research through clinical development, drug-product manufacturing, and support for commercial-scale programs. The business began in 1996 as a U.S. drug-discovery services company. Its development reflects the consolidation of specialized research and manufacturing capabilities in the global outsourcing market. In 2009, BioDuro was acquired by Pharmaceutical Product Development, a major contract research organization. In 2020, Advent International combined BioDuro with Sundia, a China-based CRO, creating BioDuro-Sundia. The combination broadened the organization’s geographic reach and connected BioDuro’s U.S. operations with Sundia’s China-based research and development infrastructure. The BioDuro name is used for U.S. and European operations, while China-based activities have also been associated with the BioDuro-Sundia identity. BioDuro’s service platform covers discovery chemistry, discovery biology, drug metabolism and pharmacokinetics, bioanalysis, drug-substance development, drug-product development, analytical testing, and manufacturing. In discovery chemistry, the company supports hit-to-lead work, medicinal chemistry, lead optimization, synthetic route development, peptide synthesis, and bioconjugation. Its work can include payload and linker development for antibody–drug conjugate programs. Discovery biology capabilities include biochemical and cellular assays, pharmacology, protein science, ligand-binding analysis, target validation, and mechanism-of-action studies. The company’s DMPK, ADME, and bioanalytical services help clients characterize how candidate compounds are absorbed, distributed, metabolized, and excreted. These activities may include in-vitro ADME testing, metabolic-stability studies, in-vivo pharmacokinetic and toxicokinetic work, and analytical method development using LC–MS/MS-based platforms. On the development and manufacturing side, BioDuro supports formulation development, solid-form screening, analytical development, and production of clinical drug products in oral and parenteral dosage forms. It also maintains high-potency capabilities for highly potent compounds, cytotoxic materials, and related programs. BioDuro works across several therapeutic and molecular modalities, including small molecules, peptides, oligonucleotides, and antibody–drug conjugates. The organization has also promoted data-driven and automated workflows intended to shorten discovery cycles. Its collaboration with Atombeat has involved combining AI-supported peptide-design methods with high-throughput peptide synthesis and iterative screening. Publicly available independent evidence remains limited regarding the real-world performance of that platform, so its impact should be understood as an area of development rather than an independently established market outcome. The company operates seven research and manufacturing campuses across the United States and China and reports a global workforce of more than 2,000 scientists. A 2021 expansion in Irvine was intended to strengthen U.S. clinical and commercial drug-product manufacturing. In 2025, BioDuro announced additional China investments, including a process-development and scale-up site in Bengbu and an OEB-5 high-potency laboratory intended for ADC payloads and highly potent active pharmaceutical ingredients. These investments underline the company’s strategy of combining geographically distributed discovery, development, and manufacturing services for biotech and pharmaceutical customers.

BioDuro was established in the United States in 1996 as a provider of drug-discovery services. Its original business model focused on supplying scientific capabilities to pharmaceutical and biotechnology organizations that needed external support for research activities. Over time, the company expanded beyond early discovery into a broader set of chemistry, biology, pharmacology, DMPK, analytical, and development services. A significant ownership and organizational milestone occurred in 2009, when BioDuro was acquired by Pharmaceutical Product Development, commonly known as PPD. The transaction placed BioDuro within a larger contract research organization and connected its discovery capabilities with a broader life-sciences services environment. The company continued to develop its capabilities in medicinal chemistry, biology, and related preclinical disciplines. In 2020, Advent International combined BioDuro with Sundia, a China-based CRO. The transaction created BioDuro-Sundia, a more geographically distributed research, development, and manufacturing organization. The combination was strategically important because it joined BioDuro’s U.S. presence with Sundia’s China-based campuses and scientific operations. The resulting organization could offer customers a wider range of services and locations, while retaining distinct brand usage: BioDuro has been used for operations in the United States and Europe, and BioDuro-Sundia has been associated with China operations. Following the combination, BioDuro broadened its CRDMO proposition. Its capabilities came to cover not only discovery chemistry and biology but also DMPK and bioanalysis, drug-substance development, formulation, analytical development, and drug-product manufacturing. The company’s platform supports small molecules as well as more complex modalities such as peptides, oligonucleotides, and antibody–drug conjugates. ADC-related work includes bioconjugation and development of payload–linker systems, while peptide activities include synthesis and screening workflows. In 2021, BioDuro expanded its Irvine operations to support clinical and commercial drug-product manufacturing. This investment strengthened the U.S. side of the organization’s development and manufacturing offering and reflected the industry’s demand for partners able to continue programs beyond discovery and preclinical research. BioDuro has also pursued technology-enabled discovery workflows. Its work with Atombeat has involved connecting AI-supported peptide design with high-throughput peptide synthesis and iterative screening. The stated objective is to reduce the time between designing, producing, and testing peptide or bioconjugate candidates. Public information does not establish the independent clinical or commercial performance of this approach, but it illustrates the company’s effort to combine outsourced laboratory services with computational design tools. In 2025, BioDuro announced further investments in China. These included a process-development and scale-up site in Bengbu and an OEB-5 high-potency laboratory for ADC payloads and highly potent active pharmaceutical ingredients. The projects expanded the organization’s ability to support process development, scale-up, and specialized high-containment work. BioDuro now describes a network of seven research and manufacturing campuses across the United States and China, with more than 2,000 scientists worldwide. Its overall evolution has been from a U.S. discovery-services provider into a multinational CRDMO offering integrated support from early research through clinical and commercial manufacturing.

1. 2025China process-development and high-potency investments

   The company announced a Bengbu process-development and scale-up site and an OEB-5 laboratory for ADC payloads and highly potent APIs.

   Source
2. 2021Irvine drug-product expansion

   BioDuro expanded its Irvine operations to support clinical and commercial drug-product manufacturing.

   Source
3. 2020Combination with Sundia

   Advent International merged BioDuro with China-based CRO Sundia to create BioDuro-Sundia.

   Source
4. 2009Acquisition by Pharmaceutical Product Development

   Pharmaceutical Product Development acquired BioDuro, placing the company within a larger global contract research organization.

   Source
5. 1996BioDuro founded in the United States

   BioDuro began operations as a U.S. drug-discovery services company.

   Source

An integrated global CRDMO for biotechnology and pharmaceutical customers seeking outsourced discovery, development, analytical, and manufacturing capabilities across multiple drug modalities.

• Discovery chemistryCRDMO service

  BioDuro’s discovery-chemistry group supports medicinal chemistry, hit-to-lead programs, lead optimization, synthetic route development, and structure–activity relationship cycles. Its work includes small-molecule synthesis, peptide synthesis, and bioconjugation, including payload and linker development for antibody–drug conjugate programs.

• Discovery biologyCRDMO service

  Discovery biology services include biochemical and cellular assay development, pharmacology, protein science, ligand-binding analytics, target validation, and mechanism-of-action studies. These capabilities support early screening and preclinical characterization across drug-discovery programs.

• DMPK, ADME, and bioanalysisPreclinical and analytical service

  BioDuro conducts in-vitro ADME studies, metabolic-stability testing, in-vivo pharmacokinetic and toxicokinetic studies, and bioanalytical method development. LC–MS/MS-based analytical workflows are used to help clients assess compound exposure and disposition during preclinical development.

• Drug-product development and manufacturingCDMO service

  The company provides formulation development, solid-form screening, analytical development, and manufacturing support for clinical and commercial drug products. Its work covers oral and parenteral dosage forms and includes capabilities for highly potent and cytotoxic compounds.

• Peptide and bioconjugation servicesSpecialized drug-modality service

  BioDuro supports peptide synthesis, peptide screening, and bioconjugation programs. The company has described workflows that combine high-throughput synthesis with iterative testing and has applied related capabilities to peptide therapeutics and antibody–drug conjugate development.

• High-potency development and manufacturingSpecialized CDMO service2025

  BioDuro operates high-potency capabilities for highly potent active pharmaceutical ingredients, cytotoxic materials, and ADC payloads. Its announced OEB-5 laboratory investment in China is intended to strengthen specialized development and handling capacity for these programs.

• 2025Invest in China process development and high-potency capabilitiesStrategy

  Growing demand for scale-up, ADC payload, and highly potent API services created a rationale for additional specialized capacity in China.

  What changed. BioDuro announced a Bengbu process-development and scale-up site and an OEB-5 laboratory for ADC payloads and highly potent APIs.

  Aftermath. The investments were intended to broaden BioDuro’s China-based development and containment capabilities, although publicly available material does not quantify their operational or financial results.

  Source
• 2021Expand Irvine drug-product manufacturingStrategy

  BioDuro identified a need to strengthen U.S. capabilities for clinical and commercial drug-product development and manufacturing.

  What changed. The company expanded its Irvine operations to support drug-product manufacturing activities.

  Aftermath. The expansion increased the company’s U.S. capacity within its integrated CRDMO offering.

  Source
• 2020Combine BioDuro with SundiaM&A

  Advent International sought to combine BioDuro’s U.S.-based operations with the China-based CRO Sundia and create a broader international CRDMO platform.

  What changed. BioDuro and Sundia were merged and operated under the BioDuro-Sundia structure, with BioDuro retained as the principal brand in the United States and Europe.

  Aftermath. The combination expanded the organization’s geographic footprint and service coverage across discovery, development, and manufacturing.

  Source

• 2025BioDuro announced new China process-development and high-potency investments

  BioDuro announced investments including a Bengbu process-development and scale-up facility and an OEB-5 laboratory for ADC payloads and highly potent active pharmaceutical ingredients.

  Other
  Source
• 2021BioDuro expanded Irvine operations for drug-product manufacturing

  The company expanded its Irvine, California operations to support clinical and commercial drug-product manufacturing, strengthening its U.S. development and production footprint.

  Other
  Source
• 2020BioDuro and Sundia combined to form BioDuro-Sundia

  BioDuro was merged with China-based CRO Sundia in a transaction associated with Advent International, creating a broader CRDMO platform serving pharmaceutical and biotechnology customers across the United States and China.

  M&A
  Source

1. BioDuro
2. BioDuro official website